Compare Eni SpA (E) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eni SpA vs TG Therapeutics Inc — how do they compare? Eni SpA trades at $55.45 (market cap $80.32B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Eni SpA is far larger — about 10.5× TG Therapeutics Inc's market cap, and Eni SpA pays a 4.4% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| E | TGTX | |
|---|---|---|
Market Cap | $80.32B | $7.64B |
Sector | Energy | Health |
52-Week High | $57.61 | $59.06 |
52-Week Low | $34.03 | $26.94 |
Enterprise Value | $105.61B | $7.84B |
Dividend Yield | 4.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eni (E) trades at $55.12, up 0.46% with a bullish technical signal supported by moving averages and ADX indicators. The company shows mixed earnings performance with Q2 2026 missing estimates despite 21.5% revenue growth, while maintaining strong cash flow generation of $13.33B from operations in 2025. Recent developments include a $3.9B share buyback increase and strategic partnerships in Cyprus gas fields and low-carbon mobility.
The stock presents value with attractive valuation multiples (P/E 12.5, P/S 0.82) and dividend yield support, though faces headwinds from volatile energy markets and recent earnings misses. Analyst consensus leans cautious with 62% hold ratings, reflecting balanced risk-reward amid production growth initiatives and commodity price exposure.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
